Added to YB: 2025-10-07
Pitch date: 2025-10-03
NVO [bullish]
Novo Nordisk A/S
Author Info
Undervalued-Shares.com finds world class companies trading at low prices. Visit the website.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.7T
Pitch Price
N/A
Price Target
120.00 (-68%)
Dividend
3.08%
EV/EBITDA
10.97
P/E
15.18
EV/Sales
5.65
Sector
Pharmaceuticals
Category
value
3 investment ideas from last night’s reader dinner - Novo Nordisk A/S
NVO: Weight loss drug duopoly w/ Eli Lilly but trades at 1/3 the multiples despite comparable fundamentals. Stock fell from DKK 1,000 to <DKK 400 after CagriSema trial showed 23% vs 25% expected weight loss, causing CEO departure. New CagriSema trial underway. 50-100% upside potential to LLY valuation parity.
Read full article (2 min)